PMM1: A Promising Drug Target / Biomarker (G5372)

Target Name: PMM1

NCBI ID: G5372

PMM1

PMM1: A Promising Drug Target / Biomarker

PMM1 (Peripheral Myeloid-derived Marker 1) is a protein that is expressed in the peripheral blood mononuclear cells (PMCs) of individuals. PMCs are a type of immune cell that play a crucial role in the immune system. They are responsible for providing the body with a barrier against infections and diseases caused by pathogens. PMM1 is one of the proteins that are expressed by PMCs. In this article, we will discuss PMM1 as a drug target and its potential as a biomarker for various diseases.

PMM1 as a drug target:

PMM1 is a potential drug target for various diseases due to its unique structure and biology. PMM1 is a monoclonal antibody (mAb) that targets a protein called CD11b. CD11b is a protein that is expressed in the cells of the immune system, including PMCs. PMM1 binds to CD11b and prevents it from interacting with its receptor, leading to the inhibition of the activity of the receptor. This results in the suppression of the immune response, which can be useful in diseases where an overactive immune response is present.

One of the advantages of PMM1 as a drug target is its ease of use. PMM1 can be easily produced and purified from a variety of sources, including human blood samples. This makes it an attractive candidate for use in clinical trials. Additionally, PMM1 does not require any special modifications to be effective, which makes it a more accessible target for drug development.

PMM1 as a biomarker:

PMM1 can also be used as a biomarker for various diseases. PMM1 is a protein that is expressed in the immune system, including PMCs. This makes it an attractive candidate for use as a biomarker for diseases that affect the immune system.

One of the benefits of using PMM1 as a biomarker is its ability to provide information about the disease progression. PMM1 is expressed in the PMCs of individuals with various diseases, including cancer, autoimmune disorders, and infections. The level of PMM1 in these cells can provide information about the severity and progression of the disease. This information can be used to guide the choice of treatment options and to monitor the effectiveness of treatments.

PMM1 is also a biomarker for certain types of cancer. PMM1 has been shown to be upregulated in various types of cancer, including breast, lung, and ovarian cancer. This increase in PMM1 levels can be used as a marker for the presence of cancer and as a target for cancer therapies.

PMM1 as a drug target:

PMM1 is also a potential drug target for various diseases due to its unique structure and biology. PMM1 is a monoclonal antibody (mAb) that targets a protein called CD11b. CD11b is a protein that is expressed in the cells of the immune system, including PMCs. PMM1 binds to CD11b and prevents it from interacting with its receptor, leading to the inhibition of the activity of the receptor. This results in the suppression of the immune response, which can be useful in diseases where an overactive immune response is present.

One of the advantages of PMM1 as a drug target is its ability to modulate the immune response. PMM1 can be used to treat diseases that are characterized by an overactive immune response, such as cancer, autoimmune disorders, and infections. By modulating the immune response, PMM1 can promote the elimination of pathogens and cancer cells. Additionally, PMM1 has been shown to have anti-inflammatory effects, which can further enhance its potential as a drug.

Conclusion:

PMM1 is a protein that is expressed in the immune system and has been shown to be involved in various immune responses. Its unique structure and biology make it an attractive candidate for use as a drug target and a biomarker for various diseases. PMM1's ability

Protein Name: Phosphomannomutase 1

Functions: Involved in the synthesis of the GDP-mannose and dolichol-phosphate-mannose required for a number of critical mannosyl transfer reactions. In addition, may be responsible for the degradation of glucose-1,6-bisphosphate in ischemic brain

The "PMM1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PMM1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets